title: Medications and monitoring in nontuberculous mycobacteria infections.
abstract: The treatment of infections caused by nontuberculous mycobacteria (NTM) is challenging because multidrug regimens with limited efficacy and considerable toxicity are required. Current treatment of NTM is largely empiric. None of the NTM drugs were specifically developed for the treatment of NTM; the rationale for their use was often extrapolated from the treatment of tuberculosis. This article reviews key features of the drugs that are most commonly used for NTM infections, and provides monitoring parameters. With this information, clinicians can make the most of the limited options available. Considerable research is needed to optimize the treatment of NTM.
authors: Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy, and Emerging Pathogens Institute, University of Florida, 1600 Southwest Archer Road, Gainesville, FL 32610-0486, USA.
authors: Eric F
authors: EF
authors: Egelund
authors: College of Medicine, and Emerging Pathogens Institute, University of Florida, 1600 Southwest Archer Road, Gainesville, FL 32610-0486, USA.
authors: Kevin P
authors: KP
authors: Fennelly
authors: Infectious Disease Pharmacokinetics Laboratory, College of Pharmacy, and Emerging Pathogens Institute, University of Florida, 1600 Southwest Archer Road, Gainesville, FL 32610-0486, USA. Electronic address: peloquin@cop.ufl.edu.
authors: Charles A
authors: CA
authors: Peloquin
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D024881:Drug Resistance, Bacterial; D006801:Humans; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy* / Q000382:microbiology; D009170:Nontuberculous Mycobacteria / Q000187:drug effects*
chemical_list: D000900:Anti-Bacterial Agents
keywords: Ethambutol; Macrolides; Mycobacterium avium complex; Nontuberculous mycobacteria; Pharmacokinetics; Rifamycins; β-Lactams